Research and Markets: Global Ophthalmic Drugs Market 2011-2015: Novartis AG and Pfizer Inc. Dominate the Market

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/mwvzrl/global_ophthalmic) has announced the addition of the "Global Ophthalmic Drugs Market 2011-2015" report to their offering.

TechNavio's analysts forecast the Global Ophthalmic Drugs market to grow at a CAGR of 9.98 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in prevalence of eye disorders. The Global Ophthalmic Drugs market has also been witnessing the trend of increased focus on combination therapies. However, the low patient compliance could pose a challenge to the growth of this market.

This report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Ophthalmic Drugs market landscape and its groth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are Alcon Inc., Allergan, Inc., Merck and Co., Inc., Novartis AG, and Pfizer Inc.

Key questions answered in this report:

- What will the market size be in 2015 and what will the growth rate be

- What are the key market trends

- What is driving this market

- What are the challenges to market growth

- Who are the key vendors in this market space

- What are the market opportunities and threats faced by the key vendors

- What are the strengths and weaknesses of the key vendors

You can request one free hour of analyst time when you purchase this report. Details provided within the report.

Executive Summary:

Commenting on the report, an analyst said: "There is an increase in the use of fixed-combination therapies for the treatment of glaucoma. Combination therapies significantly improve compliance by reducing the number and frequency of eye drop applications. The vendors in the Global Ophthalmic Drugs market are focusing more on the development of combination therapies. This is evident from the strong pipeline of combination therapies. Combination therapies are expected to reduce inflammation, the possibility of choroidal neovascularization, and vascular endothelial growth factor (VEGF) expression."

According to the report, one of the key drivers is the increasing prevalence of eye disorders such as macular degeneration, diabetic retinopathy (DR), and presbyopia in the elderly population. Moreover, incidences of glaucoma and cataracts are increasing every year. Massive numbers of people worldwide suffer from glaucoma, and this number is expected to further increase by 2020. Across the globe, many people are estimated to suffer from age-related macular degeneration (AMD (News - Alert)). The incidence of AMD is expected to increase significantly during the forecast period.

Further, the report reveals that one of the key challenges in this market is low patient compliance.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

For more information visit http://www.researchandmarkets.com/research/mwvzrl/global_ophthalmic.